These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 8413388)
1. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
5. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023 [TBL] [Abstract][Full Text] [Related]
9. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [TBL] [Abstract][Full Text] [Related]
10. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565 [TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553 [TBL] [Abstract][Full Text] [Related]
13. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Atkinson K; Downs K Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265 [TBL] [Abstract][Full Text] [Related]
14. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048 [TBL] [Abstract][Full Text] [Related]